REFERENCES
- American Thoracic Society. Standardization of spirometry. Am. Rev. Respir. Dis. 1979; 119: 831–838
- Beheshti J., Mark E. J., Akbaei H. M., Aslani J., Ghanei M. Mustard lung secrets: Long term clinicopathological study following mustard gas exposure. Pathol. Res. Pract. 2006; 202: 739–744
- Chacon R. A., Corris P. A., Dark J. H., Gibson G. J. Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation. J. Heart Lung Transplant. 2000; 19(3)263–269
- Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., Anderson J., Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003; 361(9356)449–456
- Dransfield M. T., Bailey W. C. Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. Expert Opin. Pharmacother. 2004; 5(8)1815–1826
- Ezri T., Kunichezky S., Eliraz A., Soroker D., Halperin D., Schattner A. Bronchiolitis obliterans—Current concepts. Q. J. Med. 1994; 87(1)1–10
- Fenton C., Keating G. M. Inhaled salmeterol/fluticasone propionate: A review of its use in chronic obstructive pulmonary disease. Drugs 2004; 64(17)1975–1996
- Fullmer J., Fan L., Dishop M. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-blockade. Pediatrics 2005; 116(3)767–770
- Ghanei M., Khalili A. R., Arab M. J., Mojtahedzadeh M., Aslani J., Lessan-Pezeshki M., Panahi Y., Alaeddini F. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin. Pharmacol. Toxicol. 2005; 97(5)302–305
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. U.S. Department of Health and Human Services, Bethesda, MD 2001, NHLBI/WHO workshop report, NIH publication 2701
- Martin R. J., Szefler S. J., Chinchilli V. M., Kraft M., Dolovich M., Boushey H. A., Cherniack R. M., Craig T. J., Drazen J. M., Fagan J. K., Fahy J. V., Fish J. E., Ford J. G., Israel E., Kunselman S. J., Lazarus S. C., Lemanske R. F., Jr., Peters S. P., Sorkness C. A. Systemic effect comparisons of six inhaled corticosteroid preparations. Am. J. Respir. Crit. Care Med. 2002; 165: 1377–1383
- Mason R. J. Murray & Nadel's textbook of respiratory medicine, 4th ed. Saunders, Philadelphia 2005
- Mirsadraee M., Attaran D., Boskabady M. H., Towhidi M. Airway hyperresponsiveness to methacholine in chemical warfare victims. Respiration 2005; 72(5)523–528
- O'Brien A., Russo-Magno P., Karki A., Hiranniramol S., Hardin M., Kaszuba M., Sherman C., Rounds S. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am. J. Respir. Crit. Care Med. 2001; 64(3)365–371
- Perrin-Fayolle M. Bronchiolitis obliterans in adults. Presse Med. 18 1995; 24(7)362–365
- Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 2000; 320(7246)1368–1373
- Soriano J. B., Vestbo J., Pride N. B., Kiri V., Maden C., Maier W. C. Survival in COPD patients after regular use of fluticasone propionate and salmetrol in general practice. Eur. Respir. J. 2002; 20(4)819–825
- Wong J. Y., Moon S., Beardsmore C., O'Callaghan C., Simpson H. No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis. Eur. Respir. J. 2000; 15(2)388–394